Crown Bioscience Announces Further Enhancement of its Technology Platform with New MuBase® Models and Features
October 13, 2016
(Santa Clara, Calif., Oct. 13, 2016) — Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology and metabolic disease research, has published a further enriched version of its MuBase, the world’s first online database now collating efficacy/PD and humanized models including syngeneics, GEMM, chimeric, and allograft cancer models.
The newly added models and features complement the existing annotated collection of syngeneic models, making the database a powerful, comprehensive tool, collating all models utilized during early stage in vivo pharmacology and immuno-oncology research.
MuBase offers a user-friendly experience while searching a large collection of model data, including tumor pathology, genomic characterization, and in vivo pharmacology data with standard of care and immunotherapy agents. Furthermore, recently generated immunophenotyping data by FACS analysis are available.
“These data are invaluable for researchers who need to select the right model to test their agents,” commented Qian Shi, Ph.D., vice president of cancer pharmacology and in vitro cancer biology at CrownBio. “By facilitating model selection, MuBase empowers investigators in hypothesis generating studies called MuScreen™, in which a panel of syngeneic models are used to screen for biomarkers of immune modulation to facilitate pharmacodynamic profiling and evaluation of in vivo immunotherapeutic efficacy.”
In collaboration with Nanjing Galaxy Biopharma Co. Ltd, CrownBio has recently established new chimeric models that feature functional humanized checkpoint inhibitor pathways within hosts with a functional immune system. “Our chimeric HuGEMM™ models are unique in that they allow the direct evaluation of anti-human immunotherapeutics,” said Henry Li, Ph.D., vice president of translational oncology at CrownBio. “We have also made great progress in establishing and validating new allograft models, or MuPrime™. HuGEMM and MuPrime data now available in MuBase include model strain and background, histopathology, genomic profiling via RNAseq, response to standard of care, and immuno-profiling data.”
Registered MuBase users can already take advantage of the enriched version, while new clients can simply send a request to register to start using the service from the company website.
For more information on CrownBio’s commitment to furthering the field of oncology and metabolic disease drug discovery, visit www.crownbio.com.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, please visit www.crownbio.com.